查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830978

消融设备市场

Ablation Device Market
出版日期: | 出版商: The Insight Partners | 英文 185 Pages | 商品交期: 1-5个工作天内

价格
简介目录

2024 年消融设备市场价值为 97.9 亿美元，预计到 2031 年将达到 173.8 亿美元，2025 年至 2031 年的复合年增长率预计为 8.5%。

市场洞察与分析师观点：消融术是指透过手术切除器官、结构或部分组织。消融设备利用热量（通常由射频、射频能量或雷射产生）或极冷温度来诱发轻微烧伤。消融设备市场的成长主要得益于慢性病发病率的上升、老龄人口的增加以及人们对微创手术日益增长的偏好。然而，替代治疗方案和疗法的蓬勃发展也对市场扩张构成了挑战。

成长动力与限制因素：癌症、心血管疾病和呼吸系统疾病等慢性疾病的发生率不断上升，推动了全球消融设备市场的发展。消融手术为肿瘤消融、心律不整和肺部疾病等各种疾病提供了有效的治疗方案。世界卫生组织 (WHO) 报告称，非传染性疾病 (NCD) 每年在全球造成 4,100 万人死亡。心血管疾病是 NCD 死亡的主要原因，每年夺走 1,790 万人的生命，其次是癌症（930 万人）、慢性呼吸道疾病（410 万人）和糖尿病（200 万人，包括与糖尿病相关的肾臟病死亡）。此外，美国国家癌症研究所 (NCI) 指出，癌症正日益成为全球健康问题。 2020 年，全球报告了超过 1,930 万例新发癌症病例，导致约 1,000 万人死于癌症。世界卫生组织预测，到2040年，每年将新增2,890万例癌症病例，约1,620万人死于癌症。慢性病负担的不断加重以及对治疗方案的需求正在推动对消融设备的需求。

此外，老化是慢性疾病（尤其是心血管疾病和癌症）的重要风险因素。国际抗癌联盟（UICC）指出，老化会显着增加癌症风险，老年人的癌症发生率更高。世界卫生组织估计，2015 年至 2050 年间，全球 60 岁以上人口比例将几乎翻一番，从 12% 增加到 22%。 NCBI 于 2023 年 1 月发布的一项研究预测，到 2050 年，美国 50 岁及以上人口数量将从 2020 年的 1.3725 亿增至 2.2113 亿。预计 50 岁及以上人口将至少患一种慢性病，预测显示将从 2020 年的 7,152 万人增加 99.5% 至 2050 年的 1.4266 亿。此外，预计到 2050 年将有约 1,400 万人患有多种疾病。消融手术为老年人提供了微创治疗选择，但他们可能面临更高的手术风险。因此，老年人口的成长加上慢性病盛行率的上升推动了消融设备市场的扩张。

然而，消融技术面临替代治疗方案的竞争，包括外科手术、放射疗法、全身性药物治疗和其他微创技术。医疗保健提供者可能会根据疗效、安全性、患者资格、成本效益或资源可用性等因素，根据所治疗的特定病症选择替代治疗方式。替代治疗方案的存在和偏好可能会限制消融设备的采用和使用。例如，由于公众认知度高、发展中国家先进疗法的采用有限以及外科医生不愿放弃传统疗法，手术、化疗和放射疗法等传统癌症治疗方法往往更受青睐。因此，这些因素阻碍了消融设备市场的成长。

策略洞察报告细分和范围：全球消融设备市场按设备类型、应用和最终用户进行分类。就设备类型而言，市场细分为射频设备、雷射/光消融、超音波设备、冷冻消融设备及其他。依应用，消融设备市场分为癌症治疗、心血管疾病治疗、眼科治疗、妇科治疗、泌尿科治疗、美容手术等。就最终用户而言，市场细分为医院和诊所、门诊手术中心及其他。从地理上看，消融设备市场分为北美（美国、加拿大和墨西哥）、欧洲（德国、法国、义大利、英国、俄罗斯和欧洲其他地区）、亚太地区（澳洲、中国、日本、印度、韩国和亚太其他地区）、中东和非洲（南非、沙乌地阿拉伯、阿联酋中美洲和中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲和其他地区）。

細項分析：依设备类型分类，消融设备市场包括射频设备、雷射/光消融、超音波设备、冷冻消融设备等。射频设备细分市场在2022年占据了相当大的市场份额，预计在2022年至2030年期间将呈现更高的复合年增长率。射频消融术是一种微创手术，用于治疗肌瘤、骨骼、组织、甲状腺、子宫内膜、静脉曲张等，可作为传统外科手术的替代方案。

根据应用，消融器械市场细分为癌症治疗、心血管疾病治疗、眼科治疗、妇科治疗、泌尿科治疗、美容手术等。心血管疾病治疗领域在2022年占据了较大的市场份额，预计在2022-2030年期间也将实现更高的复合年增长率。

就终端用户而言，消融设备市场分为医院和诊所、门诊手术中心和其他。 2022年，医院和诊所占据了最大的市场份额，预计在2022年至2030年期间将实现最高的复合年增长率。医院和诊所是消融设备的主要终端用户，提供广泛的医疗服务，包括需要消融的非侵入性手术。

区域分析：从地理来看，全球消融设备市场分为五个主要区域：北美、欧洲、亚太、南美和中美以及中东和非洲。预计亚太地区在 2022 年至 2030 年期间的复合年增长率最高。印度和中国等亚太国家为消融设备市场带来了巨大的成长潜力。该地区的发展中国家医疗基础设施不断改善、医疗支出不断增加以及对先进医疗技术的日益重视，为市场成长提供了机会。随着新兴市场对医疗基础设施的投资以及越来越多的医生熟悉先进的消融技术，预计对消融设备的需求将会上升，从而促进亚太地区的市场成长。

2022年，北美占据了消融设备市场的最大份额，其中美国占了最大的份额。这一趋势很可能从2022年持续到2030年。根据美国癌症协会的数据，2021年有超过190万人被诊断出罹患癌症，导致608,570人死亡。此外，在美国，每2名男性中就有1名，每3名女性中就有1名可能在其一生中被诊断出罹患癌症。癌症在人群中的高盛行率推动了美国消融设备市场的成长。

美国医疗保险和医疗补助服务中心报告显示，2021年美国全国医疗支出成长2.7%，达到4.3兆美元，人均医疗支出12,914美元。医疗支出占美国国内生产毛额（GDP）的18.3%。美国卫生与公众服务部估计，2019年至2028年，美国全国医疗支出将以每年5.4%的速度成长，到2028年将达到6.2兆美元。医疗支出的增加可能会带来更多药物研发资金，从而刺激学术领域对消融设备的需求。

消融设备市场报告范围：产业发展与未来机会：消融技术的进步大大提高了手术的有效性和安全性。新型消融设备采用射频、微波、冷冻消融和雷射等先进技术，能够精确破坏组织，同时最大限度地减少对周围健康组织的伤害。这些创新提高了成功率，拓宽了消融手术的范围，推动了市场成长。全球消融设备市场的主要参与者已采取各种倡议，包括：

全球消融设备市场的最新发展包括：

2023 年 5 月，雅培的 TactiFlex 消融导管（感测器启用）获得 FDA 批准，这是世界上第一个具有灵活尖端和接触力技术的消融导管。 2023 年 2 月，Hologic Inc. 的 NovaSure V5 全球子宫内膜消融术 (GEA) 设备在加拿大和欧洲获得医疗用途批准，具有治疗各种子宫颈和子宫解剖结构的增强功能。 2021 年 11 月，美敦力印度公司推出了用于心房颤动 (AF) 治疗的 Arctic Front 心臟冷冻消融导管系统，可实现微创冷冻球囊导管消融，这是治疗 AF 的一种治疗选择。 2021 年 1 月，美敦力公司获得 FDA 批准的 DiamondTemp 消融 (DTA) 系统，专为復发性、症状性阵发性 AF 患者而设计，特别是那些对传统药物无反应的患者。 DTA 是首款经 FDA 批准的、采用钻石的温控灌注式射频 (RF) 消融系统，目前可用于进行消融。 2020 年 12 月，Acutus Medical 在其 AcQBlate Force 消融导管和 Qubic 力感测模组获得 CE 标誌后，在欧洲推出了 AcQBlate Force 力感测消融系统。 AcQBlate Force 是市面上唯一一款采用金头、灌注式、力感测的射频消融导管，整合了 Acutus Medical 与 BIOTRONIK 合作研发的先进组件。 2020 年 11 月，雅培宣布推出 IonicRF 发生器，这是一款经 FDA 批准的设备，用于以非手术、微创的方式治疗神经系统疼痛。这款射频消融设备利用热能作用于特定神经，阻止疼痛讯号到达大脑，目前已获准在美国和欧洲销售。竞争格局和主要公司：消融设备市场的知名企业包括雅培实验室、AngioDynamics Inc、AtriCure Inc、Biotronik、波士顿科学公司、Conmed Corporation、强生公司、美敦力公司、奥林巴斯公司和施乐辉公司。这些公司专注于开发新技术、改进现有产品，并拓展地理范围以满足日益增长的全球需求，并拓宽其特色产品组合。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：消融设备市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：消融设备市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：消融设备市场－全球市场分析

  • 消融设备 - 全球市场概览
  • 消融设备－全球市场及2030年预测

第七章：消融设备市场-收入分析-按产品，2020-2030

  • 概述
  • 雷射/光设备
  • 射频设备
  • 超音波设备
  • 冷冻消融设备
  • 其他的

第 8 章：消融设备市场 - 收入分析 - 按应用，2020-2030 年

  • 概述
  • 癌症治疗
  • 整容手术
  • 泌尿科治疗
  • 心血管治疗
  • 眼科治疗
  • 妇科治疗
  • 其他的

第九章：消融设备市场-收入分析-按最终用户，2020-2030

  • 概述
  • 医院和诊所
  • 门诊手术中心（ASC）
  • 其他的

第 10 章：消融设备市场 - 收入分析，2020-2030 年 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 13 章：消融设备市场 - 主要公司简介

  • Abbott
  • Medtronic
  • Boston Scientific Corporation
  • CONMED Corporation
  • AngioDynamics
  • Smith and Nephew
  • Olympus
  • Galil Medical Inc. (Acquired by BTG International Ltd)
  • Ethicon US, LLC (subsidiary of Johnson and Johnson)
  • Stryker

第 14 章：附录

简介目录
Product Code: TIPRE00003095

The ablation device market was valued at US$ 9.79 billion in 2024 and is anticipated to reach US$ 17.38 billion by 2031, with an estimated CAGR of 8.5% from 2025 to 2031.

Market Insights and Analyst View:Ablation involves the surgical excision of an organ, structure, or part. Ablation devices utilize heat (typically produced by radio frequency, RF, energy, or lasers) or extreme cold to induce minor burns. The growth of the ablation device market is primarily driven by the rising incidence of chronic diseases, an expanding elderly population, and a growing preference for minimally invasive procedures. However, the strong presence of alternative treatment options and therapies poses a challenge to market expansion.

Growth Drivers and Restraints:The increasing occurrence of chronic diseases, including cancer, cardiovascular diseases, and respiratory ailments, propels the global ablation devices market. Ablation procedures provide effective treatment alternatives for various conditions, such as tumor ablation, cardiac arrhythmias, and pulmonary issues. The World Health Organization (WHO) reports that noncommunicable diseases (NCDs) are responsible for 41 million deaths annually worldwide. Cardiovascular diseases lead NCD deaths, claiming 17.9 million lives each year, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million, including kidney disease deaths linked to diabetes). Additionally, the National Cancer Institute (NCI) indicates that cancer is increasingly becoming a global health concern. In 2020, over 19.3 million new cancer cases were reported, resulting in approximately 10 million cancer-related deaths globally. The WHO projects that by 2040, there could be 28.9 million new cancer cases and around 16.2 million cancer-related deaths each year. The escalating burden of chronic diseases and the demand for treatment options are driving the need for ablation devices.

Moreover, aging is a significant risk factor for chronic diseases, particularly cardiovascular issues and cancer. The Union for International Cancer Control (UICC) states that aging significantly increases cancer risk, with older adults showing a higher incidence of the disease. The WHO estimates that the percentage of the global population over 60 years will nearly double from 12% to 22% between 2015 and 2050. A study published in January 2023 by NCBI predicts that the number of individuals aged 50 and older in the U.S. will reach 221.13 million by 2050, up from 137.25 million in 2020. It is expected that individuals aged 50 and above will experience at least one chronic disease, with projections indicating a 99.5% increase from 71.52 million in 2020 to 142.66 million by 2050. Additionally, around 14 million people are expected to experience multimorbidity by 2050. Ablation procedures offer minimally invasive treatment options for the elderly, who may face higher surgical risks. Thus, the growing elderly population, combined with the rising prevalence of chronic diseases, drives the expansion of the ablation devices market.

However, ablation techniques encounter competition from alternative treatment options, including surgical procedures, radiation therapy, systemic drug therapies, and other minimally invasive techniques. Healthcare providers may choose alternative treatment modalities based on factors such as effectiveness, safety, patient eligibility, cost-effectiveness, or resource availability, depending on the specific condition being treated. The presence and preference for alternative treatment options can restrict the adoption and use of ablation devices. For instance, traditional cancer treatments like surgery, chemotherapy, and radiation therapy are often favored due to high public awareness, limited adoption of advanced treatments in developing nations, and surgeons' hesitance to move away from conventional methods. Consequently, these factors hinder the growth of the ablation device market.

Strategic Insights

Report Segmentation and Scope:The global ablation device market is categorized by device type, application, and end user. In terms of device type, the market is segmented into radiofrequency devices, laser/light ablation, ultrasound devices, cryoablation devices, and others. By application, the ablation device market is divided into cancer treatment, cardiovascular disease treatment, ophthalmologic treatment, gynecological treatment, urological treatment, cosmetic surgery, and others. Regarding end users, the market is classified into hospitals and clinics, ambulatory surgical centers, and others. Geographically, the ablation device market is segmented into North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Russia, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:The ablation device market, categorized by device type, includes radiofrequency devices, laser/light ablation, ultrasound devices, cryoablation devices, and others. The radiofrequency devices segment held a significant market share in 2022 and is expected to exhibit a higher CAGR from 2022 to 2030. Radiofrequency ablation is a minimally invasive procedure utilized for treating myomas, bones, tissues, thyroid, endometrium, varicose veins, and more, serving as an alternative to traditional surgical operations.

By application, the ablation device market is segmented into cancer treatment, cardiovascular disease treatment, ophthalmologic treatment, gynecological treatment, urological treatment, cosmetic surgery, and others. The cardiovascular disease treatment segment held a larger market share in 2022 and is also projected to register a higher CAGR during 2022-2030.

In terms of end users, the ablation device market is divided into hospitals and clinics, ambulatory surgical centers, and others. In 2022, the hospitals and clinics segment held the largest market share and is expected to achieve the highest CAGR from 2022 to 2030. Hospitals and clinics are the primary end users of ablation devices, providing a wide range of medical services, including non-invasive procedures that require ablation.

Regional Analysis:Geographically, the global ablation device market is divided into five key regions: North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. Asia Pacific is projected to experience the highest CAGR from 2022 to 2030. Countries in Asia Pacific, such as India and China, present significant growth potential for the ablation devices market. Developing nations in the region, with improving healthcare infrastructure, increasing healthcare spending, and a growing focus on adopting advanced medical technologies, provide opportunities for market growth. As emerging markets invest in healthcare infrastructure and more physicians become familiar with advanced ablation techniques, the demand for ablation devices is expected to rise, enhancing market growth in Asia Pacific.

North America accounted for the largest share of the ablation device market in 2022, with the US holding the largest share of this market. This trend is likely to continue from 2022 to 2030. According to the American Cancer Society, over 1.9 million people were diagnosed with cancer in 2021, resulting in 608,570 deaths. Furthermore, 1 in 2 men and 1 in 3 women in the US are likely to be diagnosed with cancer in their lifetime. This high prevalence of cancer among the population drives the growth of the ablation device market in the US.

The US Centers for Medicare & Medicaid Services reported that national healthcare expenditure in the US rose by 2.7% in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Health spending accounted for 18.3% of the national Gross Domestic Product (GDP). The US Department of Health & Human Services estimates that national health spending will grow at an annual rate of 5.4% from 2019 to 2028, reaching US$ 6.2 trillion by 2028. An increase in healthcare spending could lead to more funding for research and development related to drugs, thereby boosting the demand for ablation devices in academic settings.

Ablation Device Market Report ScopeIndustry Developments and Future Opportunities:Technological advancements in ablation have greatly enhanced the effectiveness and safety of procedures. Newer ablation devices utilize advanced technologies such as radiofrequency, microwave, cryoablation, and laser, allowing for precise tissue destruction while minimizing damage to surrounding healthy tissues. These innovations have improved success rates and broadened the scope of ablation procedures, driving market growth. Key players in the global ablation device market have undertaken various initiatives, including:

Recent developments in the global ablation device market include:

In May 2023, Abbott received FDA approval for its TactiFlex Ablation Catheter (Sensor Enabled), marking the world's first ablation catheter with a flexible tip and contact force technology.

In February 2023, Hologic Inc.'s NovaSure V5 global endometrial ablation (GEA) device was approved for medical use in Canada and Europe, featuring enhanced capabilities for treating a wide range of cervical and uterine anatomies.

In November 2021, Medtronic India launched the Arctic Front Cardiac Cryoablation Catheter System for atrial fibrillation (AF) treatment, enabling minimally invasive cryoballoon catheter ablation, a therapeutic option for managing AF.

In January 2021, Medtronic plc received FDA approval for the DiamondTemp Ablation (DTA) system, designed for patients with recurrent, symptomatic paroxysmal AF, particularly those unresponsive to conventional drugs. The DTA is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds, currently available for delivering ablations.

In December 2020, Acutus Medical launched the AcQBlate Force Sensing Ablation System in Europe after securing the CE Mark for the AcQBlate Force ablation catheter and the Qubic Force Sensing Module. The AcQBlate Force is the only commercially available gold-tipped, irrigated, force-sensing radiofrequency ablation catheter on the market, integrating advanced components through Acutus Medical's partnership with BIOTRONIK.

In November 2020, Abbott announced the launch of the IonicRF Generator, an FDA-cleared device for delivering a nonsurgical, minimally invasive treatment for managing pain in the nervous system. This RF ablation device targets specific nerves using heat to block pain signals from reaching the brain, and is approved for sale in the US and Europe.

Competitive Landscape and Key Companies:Prominent players in the ablation device market include Abbott Laboratories, AngioDynamics Inc, AtriCure Inc, Biotronik, Boston Scientific Corporation, Conmed Corporation, Johnson and Johnson, Medtronic PLC, Olympus Corporation, and Smith & Nephew PLC. These companies are focused on developing new technologies, enhancing existing products, and expanding geographically to meet the growing global demand and broaden their specialty product portfolios.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Ablation Device Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Ablation Device Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Ablation Device Market - Global Market Analysis

  • 6.1 Ablation Device - Global Market Overview
  • 6.2 Ablation Device - Global Market and Forecast to 2030

7. Ablation Device Market - Revenue Analysis (USD Million) - By Product, 2020-2030

  • 7.1 Overview
  • 7.2 Laser/Light Devices
  • 7.3 Radiofrequency Devices
  • 7.4 Ultrasound Devices
  • 7.5 Cryoablation Devices
  • 7.6 Others

8. Ablation Device Market - Revenue Analysis (USD Million) - By Application, 2020-2030

  • 8.1 Overview
  • 8.2 Cancer Treatment
  • 8.3 Cosmetic Surgery
  • 8.4 Urological Treatment
  • 8.5 Cardiovascular Treatment
  • 8.6 Ophthalmologic Treatment
  • 8.7 Gynecological Treatment
  • 8.8 Others

9. Ablation Device Market - Revenue Analysis (USD Million) - By End Users, 2020-2030

  • 9.1 Overview
  • 9.2 Hospitals and Clinics
  • 9.3 Ambulatory Surgical Centers (ASCs)
  • 9.4 Others

10. Ablation Device Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Ablation Device Market Overview
    • 10.1.2 North America Ablation Device Market Revenue and Forecasts to 2030
    • 10.1.3 North America Ablation Device Market Revenue and Forecasts and Analysis - By Product
    • 10.1.4 North America Ablation Device Market Revenue and Forecasts and Analysis - By Application
    • 10.1.5 North America Ablation Device Market Revenue and Forecasts and Analysis - By End Users
    • 10.1.6 North America Ablation Device Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Ablation Device Market
        • 10.1.6.1.1 United States Ablation Device Market, by Product
        • 10.1.6.1.2 United States Ablation Device Market, by Application
        • 10.1.6.1.3 United States Ablation Device Market, by End Users
      • 10.1.6.2 Canada Ablation Device Market
        • 10.1.6.2.1 Canada Ablation Device Market, by Product
        • 10.1.6.2.2 Canada Ablation Device Market, by Application
        • 10.1.6.2.3 Canada Ablation Device Market, by End Users
      • 10.1.6.3 Mexico Ablation Device Market
        • 10.1.6.3.1 Mexico Ablation Device Market, by Product
        • 10.1.6.3.2 Mexico Ablation Device Market, by Application
        • 10.1.6.3.3 Mexico Ablation Device Market, by End Users
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

13. Ablation Device Market - Key Company Profiles

  • 14.1 Abbott
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Medtronic
  • 14.3 Boston Scientific Corporation
  • 14.4 CONMED Corporation
  • 14.5 AngioDynamics
  • 14.6 Smith and Nephew
  • 14.7 Olympus
  • 14.8 Galil Medical Inc. (Acquired by BTG International Ltd)
  • 14.9 Ethicon US, LLC (subsidiary of Johnson and Johnson)
  • 14.10 Stryker

14. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud